The PAM50 breast cancer classifier successfully split prostate cancer samples into luminal and basal subtypes with ties to patient outcomes and treatment response.
The company plans to outlicense the assay, developed using a custom Affymetrix microarray, to an interested partner.
The new algorithm, called TOPSPIN, complements the company's MMprofiler test. It is considering making TOPSPIN-generated data available to its MMprofiler patients.
The OncoArray Consortium researchers also uncovered a new candidate susceptibility gene for low-grade and borderline serous epithelial ovarian cancer.
Scotland's Arrayjet will provide the Bronx-based NYBC with microarray instrumentation, printing, and expertise under an approximately $250,000 contract.
The company announced the new product, which covers variants across 600 genes, this week, and said it will be available to customers next month.
The company published a new study of average- and high-risk patients showing that the test better predicted metastasis in patients treated with radiation and hormonal therapy.
The consortium aims to profile up to 800 multiple myeloma patient samples using the Affymetrix platform with a goal of developing a list of predictive biomarkers.
The new company believes it can be the dominant clearinghouse for genome analysis apps or other tools, with free and unlimited storage of users' genomic data.
The firm will adapt multiplex panels for prognosis of septic shock patients to its array-based portable diagnostic platform.
The Associated Press reports that a state board in Texas has asked ANDE, a maker of rapid DNA machines, to halt its work there.
James Wyngaarden, the former director of the US National Institutes of Health, has died at 94, according to Duke University School of Medicine.
Researchers find that a 30-year-old skull comes from a narwhal-beluga hybrid, according to Science News.
In Nature this week: study of value diversity in GWAS, Epstein-Barr virus subtypes linked to nasopharyngeal carcinoma risk, and more.